Drug Profile
Pandemic H5N1 vaccine - Tria Bioscience/Immune Design
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator TRIA Bioscience
- Developer Immune Design; TRIA Bioscience
- Class Influenza A virus H5N1 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus H5N1 subtype
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Influenza A virus H5N1 subtype (Prevention) in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype(Prevention) in USA
- 14 Jul 2016 Preclinical trials in Influenza-A virus H5N1 subtype (Prevention) in USA (unspecified route)